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Purpose: To investigate the changes and correlations of the serum inflammation 
factors levels and left ventricular (LV) structure and function in patients with acute 
ST segment elevation myocardial infarction (STEMI). Materials and Methods: 
A prospective study was performed on 70 STEMI patients and 70 control subjects. 
Serum levels of interleukin-6 (IL-6), soluble CD40 ligand (sCD40L), metallopro-
teinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were 
measured by sandwich enzyme-linked immunosorbent assay (ELISA), and cardi-
ac structure and function were assessed by echocardiography at admission and 
3-year follow-up. Results: We found that the levels of serum IL-6, sCD40L and 
MMP-9 increased steadily among control subjects, remote myocardial infarction 
and acute STEMI patients, and the level of TIMP-1 elevated remarkly at 3-year 
follow-up visit in STEMI. The admission level of serum MMP-9 positively corre-
lated with LV end-diastolic and end-diastole volume (r=0.294, p=0.022; r=0.269, 
p=0.036, respectively), and TIMP-1 positively correlated with E/A ratio (r=0.278, 
p=0.044) at 3-year follow-up. Conclusion: The study indicates that admission lev-
els of serum MMP-9 and TIMP-1 closely correlated with left ventricular structure 
and function, which may be involved in the process of post-infarction remodeling 
of myocardium.
Key Words:    Acute ST segment elevation myocardial infarction, metalloproteinase-9, 
tissue inhibitor of metalloproteinase-1, left ventricular remodeling
INTRODUCTION
There is increased recognition that inflammation plays a key role in the pathogene-
sis of atherosclerosis and its complications.1 Recently, attention has been focused 
on the potential role of circulating inflammatory markers as risk predictors to in-
dentify patients who are more likely to suffer a clinical event. In patients with 
myocardial infarction, the progressive left ventricular (LV) dilation, that is, ven-
tricular remodeling, is linked intimately to adverse prognosis. A simple plasma 
marker that can allow early risk stratification would benefit patients in need of in-
tensive therapy. The cardiac extracellular matrix (ECM), the connective tissue Jing Tan and Qi Hua
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or patients receiving treatment with anti-inflammatory drugs. 
Patients with acute or chronic infections and autoimmune 
disease were also excluded from the study. The study proto-
col was approved by the ethics committee of our institution, 
and written informed consent was obtained from all partici-
pating subjects.
Clinical data collection
Demographic data, lifestyle, environmental factors, medical 
history and treatment were collected in the hospital. Modifi-
able risk factor reassessment, event or complications, and 
current therapy were recorded at 3-year follow-up visit. A 
person who reported smoking at least one cigarette per day 
for at least one year were defined as current smokers. Indi-
cate the negative life events occurred in the past 6 months 
(i.e. serious illness or death in family member, divorce or 
separation, forced to change job, feelings of insecurity at 
work, serious financial trouble, and being legally prosecut-
ed). Height, weight and waist circumference were mea-
sured, and body mass index was calculated as the weight in 
kilograms divided by the square of the height in meters.  
Laboratory procedures
In STEMI patients, peripheral venous blood was drawn im-
mediately after admission and at the 3-year follow-up visit. 
In control subjects, blood samples were collected after an 
overnight fast at baseline. Sample after clotting were centri-
fuged at 2500 rpm for 10 min, and the serum was frozen 
and stored at -70ºC until analyzed. Sandwich enzyme-
linked immunosorbent assay was performed for measuring 
concentrations of serum IL-6, MMP-9 and TIMP-1, using 
Quantikine R&D Systems commercial kits, and of serum 
sCD40L using Bender Medsystems commercial kits. The 
lower detection limits were 0.7 pg/mL for IL-6, 0.156 ng/
mL for MMP-9, 0.08 ng/mL for TIMP-1 and 0.095 ng/mL 
for sCD40L. The average inter- and intra-assay coefficients 
of variation were <10% for all assays. 
Echocardiographic assessment
M-mode and 2-dimensional echocardiography and Doppler 
ultrasound assessment were carried out at the time of ad-
mission and 3-year follow-up visit, by a single operator us-
ing a HP 7500 or IE 33 scanner. The study required record-
ing of 10 cycles of two-dimensional (2D) parasternal long- 
and short-axis LV views and 10 cycles of M-mode with 
optimal cursor beam orientation in each view. If the 2D 
guided M-mode beam could not be optimally oriented, a 
scaffold on which cellular elements are arranged, plays a vi-
tal role in the maintenance of myocardial structure and func-
tion, particularly that of the LV. Physiological integrity of 
ECM structure is largely under the control of the matrix me-
talloproteinase (MMPs) family of endopeptidases, and a fine 
balance between MMPs and tissue inhibitors of MMPs 
(TIMPs) is essential for maintaining the integrity of the high-
ly organized and dynamic matrix that provides structural 
support for myocytes and a medium for non-myocytes, pro-
teins, and signaling molecules.2 Previous studies reported 
that the activation of MMPs that degrade the extracellular 
matrix has been linked to adverse LV remodeling post-myo-
cardial infarction.3,4 Interleukin-6 (IL-6) and soluble CD40 li-
gand (sCD40L) also have been shown to be predictors of ad-
verse outcome in patients with coronary artery disease 
(CAD).5,6 However, a limitation of the previous studies is that 
inflammation markers were measured only at a single time 
point, and changes during follow-up were not measured. In 
this study, the circulating serum levels of the inflammatory 
markers (IL-6, sCD40L, MMP-9 and TIMP-1) were deter-
mined and echocardiographic assessment was carried out in 
patients with acute ST-segment elevation myocardial infarc-
tion (STEMI) at admission and 3-year follow-up visit, and 
we then evaluated the changes of the above inflammatory 
markers levels during 3-years follow-up period and the cor-
relations between the above inflammatory markers with LV 
structure and function post-myocardial infarction.
MATERIALS AND METHODS
　　　
Study subjects
A prospective, cohort study was performed on 70 STEMI 
patients with first STEMI who were admitted to our insti-
tute within 6 h of symptoms onset, and 70 age- and gender- 
matched subjects as control, who had no CAD. Acute STE-
MI was defined as the presence of typical prolonged (>30 
min) chest pain accompanied by typical ST segment eleva-
tion ≥0.2 mV in two or more contiguous leads on the stan-
dard 12-lead electrocardiogram (ECG) and abnormal in-
crease of MB fraction of creatine kinase greater than twice 
the normal upper limit. Patients with equivocal or uninter-
pretable ECGs (i.e. left bundle branch block, paced rhythm, 
or persistent ST-segment elevation after a previous myocar-
dial infarction) were not included in the study. 
The present study did not include patients with a history 
of hematological, neoplastic, renal, liver or thyroid disease, MMP-9/TIMP-1 and LV Remodeling
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they were natural log-transformed. The normality of 
sCD40L, MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio was 
achieved, and one-way analysis of variance and Post Hoc 
test were used; Kruskal-Wallis and Mann-Whitney test 
were used for IL-6 among three groups since the variable 
was non-normally distributed even after log transformation. 
Qualitative data are presented as numbers (percentages), 
and Chi-square tests were performed for categorical vari-
ables. Correlation analysis between variables of the study 
was made by means of Spearman’s correlation coefficient r 
for continuous variables with non-normal distribution. For 
all tests, a 2-tailed p<0.05 was considered statistically sig-
nificant. All calculations were made using SPSS statistical 
software for Windows (version 12.0).
RESULTS
 
Clinical characteristics 
The baseline features of the study population are shown in 
Table 1. There were no significant differences in any of the 
clinical variables among the two patient groups. 
Serum inflammatory markers levels
Significant differences in the levels of IL-6, sCD40L, MMP-
2D long-axis view was used to obtain linear measurements 
of the LV cavity [LV end-diastolic diameter (LVEDD) and 
LV end-systolic diameter (LVESD)] and walls. LV mass 
was estimated using the anatomically validated formula of 
Devereux. The indices that adjusted LV mass (LVM) was 
LV mass index (LVMI), defined as LVM/body surface area. 
The relative wall thickness was calculated as 2 posterior 
wall/LVEDD. LV end-systolic volume (LVESV), LV end-
diastolic volume (LVEDV), and LV ejection fraction 
(LVEF) were estimated using the biplanar modified Simp-
son’s rule from apical 2 and 4 chamber views. LV diastolic 
function was evaluated by the following pulse-wave Dop-
pler echocardiographic parameters: early (E)/late (A) ratio, 
indicating the pattern of LV diastolic filling, measured by 
pulse-wave Doppler flow pattern at mitral anulus traced 
electronically to measure peak velocities of early and late 
diastolic LV filling, that is, early (E) and late (A) transmitral 
peak flow velocities.
Statistical analysis
Data are expressed as means±SD or median and interquar-
tile ranges, as appropriate. Unpaired or paired Student’s t-
test was used to evaluate differences in normally distributed 
continuous variables between the two groups. Because of 
non-normal distribution of inflammatory markers variables, 
Table 1. Baseline Characteristics of the Study Population
Variables STEMI (n=70) Control (n=70) p value
Male, n (%)          59 (84.3) 60 (85.7) 0.813
Age (yrs)        59.20±11.32   57.89±10.55 0.479
BMI (kg/m
2)        25.33±2.70 24.97±3.17 0.473
Waist circumference (cm)        91.62±11.53   88.56±10.17 0.099
Hypertension, n (%)          29 (41.4) 29 (41.4) 1.000
Hypercholesterolemia, n (%)          14 (20.0) 22 (31.4) 0.122
Diabetes mellitus, n (%)            9 (12.9)   9 (12.9) 1.000
Current smokers, n (%)          46 (65.7) 38 (54.3) 0.168
Sedentary lifestyle, n (%)          32 (45.7) 36 (52.2) 0.446
Negative life events occurred in the past 6 months, n (%)          19 (27.1) 18 (25.7) 0.848
Medication -
β blocker use, n (%)          63 (90)
ACE-I use, n (%)          68 (97.1)
Statin use, n (%)          68 (97.1)
Antiplatelet agents, n (%)          70 (100)
Reperfusion therapy, n (%)          56 (80.0) -
Peak CK (u/L) 1514.00 (695.00-3059.00) -
Peak CK-MB (u/L)   121.00 (53.00-210.00) -
Peak TnI (ng/mL)     42.65 (13.18-134.80) -
Killip’s class ≥II, n (%)          15 (21.4) -
BMI, body mass index; ACE-I, angiotensin-converting enzyme inhibitors; CK, creatine kinase; CK-MB, creatine kinase-myocardial fraction; Tn-I, Troponin I; 
STEMI, segment elevation myocardial infarction; Age, BMI and waist circumference are presented as mean±standard deviation; Peak CK, CK-MB and TnI 
are presented as medians (25th-75th percentile); categorical variables are presented as number (%).Jing Tan and Qi Hua
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p=0.014 and p=0.034, respectively), and LVEF was im-
paired (p=0.006), compared with baseline (Table 3). 
There was no association between the levels of IL-6, 
sCD40L, MMP-9, TIMP-1 and echocardiographic markers of 
LV structure or function at the same time. However, MMP-9 
measured at admission showed weak association with great 
LVEDD and LVEDV (r=0.294, p=0.022 and r=0.269, 
p=0.036, respectively), and TIMP-1 positively correlated 
with E/A ratio at follow-up (r=0.278, p=0.044).
DISCUSSION
The main findings of this study are that the levels of serum 
IL-6, sCD40L and MMP-9 were steadily increased among 
9 and TIMP-1 were detected among the three studied 
groups, as shown in Table 2. The levels of IL-6 and sCD40L 
were found to be elevated in acute STEMI as compared to 
controls (both p<0.001); In patients with remote myocardi-
al infarction (at 3-year follow-up visit), the levels of IL-6, 
sCD40L, MMP-9 and MMP-9/TIMP-1 ratio were signifi-
cantly reduced compared admission levels (all p<0.001); 
The levels of IL-6, sCD40L, MMP-9, and TIMP-1 were 
still higher at 3-year follow-up visit in STEMI patients com-
pared to controls (p<0.001, p<0.001, p<0.001 and p=0.039, 
respectively).
Echocardiographic assessment
After 3-years, LVEDD, LVM, LVMI, LVESV and E/A ra-
tio were significantly increased (p=0.045, p=0.048, p=0.047, 
Table 2. Serum Levels of Inflammatory Markers
Variables
STEMI (n=70)
Control (n=70)
p value
STEMI at 
admission
STEMI at 3 yrs 
follow-up visit
Admission vs. 
3 yrs follow-up 
visit
3 yrs 
follow-up 
visit vs. control
Admission vs. 
control
IL-6 (pg/mL) 5.30 
  (4.22-7.37)
3.50 
  (3.11-4.06)
2.87 
  (2.39-3.44) <0.001 <0.001 <0.001
sCD40L (ng/mL) 4.52 
  (2.84-6.41)
2.29 
  (0.71-4.64) 
1.31 
  (0.74-4.10) <0.001 <0.001 <0.001
MMP-9 (ng/mL) 1130.00 
  (624.50-1750.00)
1035.00 
  (734.00-1372.50)
768.00 
  (533.50-1132.50) <0.001 <0.001   0.189
TIMP-1 (ng/mL) 246.00 
  (155.00-393.00)
400.00 
  (305.50-490.00)
234.50 
  (167.50-316.50)   0.174   0.039   0.599
MMP-9/TIMP-1 ratio 4.26 
  (2.99-5.95)
2.58 
  (1.91-3.59) 
3.39 
  (2.25-4.81) <0.001 <0.001   0.064
IL-6, interleukin-6; sCD40L, soluble CD40 ligand; MMP-9, metalloproteinase-9; TIMP-1, tissue inhibitor of metalloproteinase-1; STEMI, segment elevation 
myocardial infarction. 
Data are presented as medians (25th-75th percentile).
Table 3. Changes in Echocardiographic Parameters from Admission to 3 Years Follow-Up Visit in STEMI Patients 
Variables STEMI (at admission) (n=70) STEMI (at 3 yrs follow-up visit) (n=70) p value
IVSd (cm)   1.02±0.11   0.96±0.16 0.110
LVPWd (cm)   0.98±0.07   0.99±0.12 0.677
LVEDD (cm)   5.15±0.54   5.49±0.69 0.045
LVM (g) 227.38±56.08 261.31±77.32 0.048
LVMI (g/m
2) 125.45±30.22 143.54±37.09 0.047
RWT   0.39±0.04   0.36±0.06 0.051
LVEDV (mL) 128.44±32.15 147.83±43.92 0.061
LVESV (mL)   49.54±22.76   64.38±30.78 0.014
LVEF (%)   61.71±10.03 55.61±8.91 0.006
E/A ratio   0.75±0.18   0.96±0.35 0.034
IVSd, interventricular septal thickness in diastole; LVPWd, left ventricular posterior wall thickness in diastole; LVEDD, left ventricular end-diastolic dimen-
sion; LVM, left ventricular mass; LVMI, left ventricular mass index; RWT, relative wall thickness; LVEDV, left ventricular end-diastolic volume; LVESV, left 
ventricular end-systolic volume; LVEF, left ventricular ejection fraction. 
E, mitral peak flow velocity of early filling; A, peak flow velocity of late filling.
Data are presented as mean±standard deviation.MMP-9/TIMP-1 and LV Remodeling
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remodeling takes place. Previous studes12-15 have reported   
that patients with ACS exhibited significantly higher levels 
of MMP-9 and TIMP-1 than those with stable angina and 
normal control subjects, and the higher levels were related 
to the presence of plaque rupture in the culprit lesion. In our 
pervious study,16 we found that acute STEMI patients ex-
hibited significantly higher level of MMP-9 and slightly el-
evated TIMP-1 as compared to control, therefore, the 
MMP-9/TIMP-1 ratio was remarkably increased, indicating 
that an imbalance between MMP-9 and TIMP-1 in the mi-
cro-environment of the vulnerability atherosclerotic plaques 
may be responsible at least in part for plaque disruption 
eventually leading to occurrence of cardiovascular events. 
In the present study, we failed to find any significant differ-
ence of the MMP-9 and TIMP-1 levels between acute STE-
MI patients and control due to a small sample size. Howev-
er, we found that the levels of MMP-9 and the ratio of 
MMP-9/TIMP-1 were significantly higher in acute STEMI 
patients than those in remote STEMI, which also add 
weight to our previous findings.
MMPs and TIMPs participate not only in the process of 
atherogenesis and atherosclerotic plaque destabilization, 
they may also influence LV dilation and function impair-
ment after myocardial infarction.17-20 In the present study, 
we found that MMP-9 measured at admission showed a 
positive association with great LVEDD and LVEDV at 
3-year follow-up visit, which add the additional weight to 
the above-described notion. We also found that TIMP-1 
was elevated remarkly in remote myocardial, and that 
TIMP-1 at admission positively correlated with E/A ratio 
measured in the subsequent follow-up period. Thus, we 
speculate that TIMP-1, following the activation of MMP-9, 
plays a protective role during the phase of LV remodeling 
and function impairment. Indeed, MMPs inhibition has 
been postulated as a potential therapeutic intervention in 
patients with acute myocardial infarction. Beneficial effects 
of selective MMP inhibition on regional myocardial geom-
etry post-myocardial infarction were shown in experiment 
animal models.21 Miyazaki, et al.22 found that LV remodel-
ing might be suppressed in association with MMP-9 sup-
pression in acute myocardial infarction patients treated with 
percutaneous coronary intervention and regular dose or 
half-dose-combination of renin-angiotensin system inhibi-
tors. However, the broad spectrum MMP inhibitor PG-
116800 failed to attenuate adverse LV remodeling after 
myocardial infarction in prevention of myo  cardial infarc-
tion early remodeling trial.23 Therefore, selective MMP in-
control subjects, remote myocardial infarction and acute 
STEMI patients, that TIMP-1 was elevated, and MMP-9/
TIMP-1 ratio decreased markedly in remote STEMI, that 
MMP-9 measured at admission showed a positive associa-
tion with great LVEDD and LVEDV, and that TIMP-1 pos-
itively correlated with E/A ratio measured at subsequent 
follow-up period. The results suggest that elevated levels of 
IL-6, sCD40L, and MMP-9 and the imbalance of MMP-9/
TIMP-1 system are involved in the process of plaque rup-
ture, leading to the incidence of myocardial infarction, and 
that MMP-9/TIMP-1 may also be linked to the post-infarc-
tion remodeling of myocardium, probably leading to heart 
failure.
Acute coronary syndrome (ACS) is triggered by dys-
functional endothelial and atherosclerotic plaque instability. 
The stage of plaque instability is that pro-inflammatory cy-
tokines and chemoattractants induce leukocyte chemoat-
traction to the endothelium, and together with other triggers 
such as the CD40L-CD40 co-stimulation system activate 
plaque monocytes (macrophages). The macrophages then 
produce MMPs that disintegrate extra-cellular plaque ma-
trix, causing coronary plaque instability.7 IL-6 is a circulat-
ing cytokine known to be secreted from a number of differ-
ent cells including activated macrophages and lymphocytes, 
which could stimulates hepatocytes to synthesize acute 
phase response proteins such as C-reactive protein and fi-
brinogen. The CD40L on T-cells binding to the CD40 re-
ceptor on macrophages is involved in the multiple stages of 
atherosclerosis and ACS, inducing macrophages to secrete 
tissue factor, up-regulating the expression of adhesion mol-
ecules, and activating secretion of MMPs. Previous study8,9 
have shown, in agreement with our results, that the concen-
tration of IL-6 and sCD40L are significantly elevated from 
stable CAD to ACS, as compared to control, possibly sup-
porting their role in plaque instability and rupture. 
MMPs are a tightly regulated group of zinc-dependent 
peptidases that participate in matrix turnover in both nor-
mal and pathological conditions.10 In the present study, we 
studied one member from the family of gelatinases, such as 
MMP-9, which has been found highly expressed in the 
shoulder regions of advanced atherosclerotic lesions and 
contributes to plaque instability.11 The main endogenous 
MMPs inhibitors are TIMPs, and TIMP-1 inhibits most 
MMPs except for MMP-2. Under normal circumstances, 
the activeity of MMPs and TIMPs maintain a balance be-
tween connective tissue synthesis and degradation. When 
the balance is disturbed, the undesired tissue destruction or Jing Tan and Qi Hua
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Eur J Clin Invest 2007;37:623-8.
9. Wang J, Zhang S, Jin Y, Qin G, Yu L, Zhang J. Elevated levels of 
platelet-monocyte aggregates and related circulating biomarkers 
in patients with acute coronary syndrome. Int J Cardiol 2007;115: 
361-5.
10. Lijnen HR. Plasmin and matrix metalloproteinases in vascular re-
modeling. Thromb Haemost 2001;86:324-33.
11. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identifi-
cation of 92-kD gelatinase in human coronary atherosclerotic le-
sions. Association of active enzyme synthesis with unstable angi-
na. Circulation 1995;91:2125-31.
12. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumu-
ra K. Plasma levels of matrix metalloproteinase-9 and tissue in-
hibitor of metalloproteinase-1 are increased in the coronary circu-
lation in patients with acute coronary syndrome. Am Heart J 
2001;141:211-7.
13. Derosa G, D’Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros 
E, et al. Comparison between metalloproteinases-2 and -9 in 
healthy subjects, diabetics, and subjects with acute coronary syn-
drome. Heart Vessels 2007;22:361-70.
14. Shu J, Ren N, Du JB, Zhang M, Cong HL, Huang TG. Increased 
levels of interleukin-6 and matrix metalloproteinase-9 are of car-
diac origin in acute coronary syndrome. Scand Cardiovasc J 2007; 
41:149-54.
15. Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, 
Ehara S, et al. Comparison of levels of serum matrix metallopro-
teinase-9 in patients with acute myocardial infarction versus un-
stable angina pectoris versus stable angina pectoris. Am J Cardiol 
2006;97:175-80. 
16. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated se-
rum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and 
tissue inhibitor of metalloproteinase-1 in patients with acute ST-
segment elevation myocardial infarction. Clin Cardiol 2008;31: 
413-8.
17. Matsunaga T, Abe N, Kameda K, Hagii J, Fujita N, Onodera H, et 
al. Circulating level of gelatinase activity predicts ventricular re-
modeling in patients with acute myocardial infarction. Int J Cardi-
ol 2005;105:203-8.
18. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, 
Clark LL, et al. Specific temporal profile of matrix metalloprotein-
ase release occurs in patients after myocardial infarction: relation 
to left ventricular remodeling. Circulation 2006;114:1020-7. 
19. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of 
matrix metalloproteinases and their inhibitors after myocardial in-
farction: a temporal and spatial window. Cardiovasc Res 2006;69: 
604-13. 
20. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, 
et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix 
metalloproteinase-9: novel indicators of left ventricular remodel-
ling and prognosis after acute myocardial infarction. Eur Heart J 
2008;29:2116-24. 
21. Apple KA, Yarbrough WM, Mukherjee R, Deschamps AM, Esco-
bar PG, Mingoia JT, et al. Selective targeting of matrix metallo-
proteinase inhibition in post-infarction myocardial remodeling. J 
Cardiovasc Pharmacol 2006;47:228-35.
22. Miyazaki S, Kasai T, Miyauchi K, Miyazaki T, Akimoto Y, Takagi 
A, et al. Changes of matrix metalloproteinase-9 level is associated 
with left ventricular remodeling following acute myocardial in-
farction among patients treated with trandolapril, valsartan or 
both. Circ J 2010;74:1158-64.
hibition seems to be the better solution.
The limitations of our study should be considered. First, 
although significant, the associations between MMP-9, 
TIMP-1 and LV remodeling were relatively weak, which 
can not be entirely due to relatively small sample size, nev-
ertheless, a larger population is needed to confirm our find-
ings. Second, we should study the change of the inflamma-
tory markers during the period between admission and 
discharge, and then select the highest levels in the acute 
state. Ideally, control group should be the patients with sta-
ble CAD and healthy subjects, so as to observe the deffer-
ent levels of the inflammatory markers, and elucidate the 
role of inflammation in the different phases of CAD. Third, 
the development of ventricular remodeling and function 
impairment after myocardial infarction are strongly affect-
ed by the infracted area and drug treatment during follow-
up period, and these factors should not be excluded in the 
study.
In conclusion, the admission levels of serum MMP-9 and 
TIMP-1 closely correlated with left ventricular structure 
and function, which may be involved in the process of post-
infarction remodeling of myocardium.
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